Mercer Global Advisors Inc. ADV Buys Shares of 2,029 Haemonetics Co. (HAE)

Mercer Global Advisors Inc. ADV bought a new position in Haemonetics Co. (NYSE:HAE) during the first quarter, according to its most recent filing with the SEC. The firm bought 2,029 shares of the medical instruments supplier’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Haemonetics by 40.2% during the third quarter. JPMorgan Chase & Co. now owns 709,853 shares of the medical instruments supplier’s stock valued at $81,335,000 after acquiring an additional 203,656 shares during the period. Vanguard Group Inc raised its holdings in shares of Haemonetics by 1.9% during the third quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after acquiring an additional 107,357 shares during the period. Cardinal Capital Management raised its holdings in shares of Haemonetics by 2.1% during the fourth quarter. Cardinal Capital Management now owns 8,100 shares of the medical instruments supplier’s stock valued at $810,000 after acquiring an additional 163 shares during the period. First Citizens Bank & Trust Co. acquired a new stake in shares of Haemonetics during the fourth quarter valued at approximately $230,000. Finally, Bank of Montreal Can raised its holdings in shares of Haemonetics by 17.8% during the fourth quarter. Bank of Montreal Can now owns 2,052 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 310 shares during the period. Institutional investors own 98.31% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Haemonetics from a “sell” rating to a “hold” rating in a report on Tuesday, April 9th. ValuEngine lowered shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. Raymond James upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Tuesday. Barrington Research boosted their price target on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a report on Wednesday, February 6th. Finally, TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $118.60.

HAE stock opened at $99.47 on Thursday. Haemonetics Co. has a 52-week low of $80.24 and a 52-week high of $117.56. The company has a current ratio of 2.44, a quick ratio of 1.62 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.82 billion, a PE ratio of 41.62, a PEG ratio of 2.41 and a beta of 0.85.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.06. The firm had revenue of $249.30 million for the quarter, compared to analyst estimates of $250.62 million. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 EPS. Equities research analysts anticipate that Haemonetics Co. will post 2.9 EPS for the current fiscal year.

In other Haemonetics news, VP Dan Goldstein sold 3,206 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $88.90, for a total value of $285,013.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Christopher Simon sold 57,587 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $94.51, for a total transaction of $5,442,547.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,496 shares of company stock worth $6,479,049. Company insiders own 1.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Mercer Global Advisors Inc. ADV Buys Shares of 2,029 Haemonetics Co. (HAE)” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.themarketsdaily.com/2019/05/16/mercer-global-advisors-inc-adv-buys-shares-of-2029-haemonetics-co-hae.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Why Net Income is Important to Investors

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.